Health

KFSHRC Conducts 48% of Clinical Trials in Saudi Arabia During the First Half of 2025

RIYADH, Saudi Arabia, Sept. 10, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) led Saudi healthcare…

10 months ago

Saudi Food and Drug Authority, AAMI Partner on Medtech Best Practices

Arlington, Virginia, Sept. 10, 2025 (GLOBE NEWSWIRE) -- The Association for the Advancement of Medical Instrumentation (AAMI) has signed a memorandum…

10 months ago

Booking Health Expands Access to Dendritic Cell Therapy After Study Confirms Survival Benefit in Glioblastoma Patients

September 09, 2025 13:19 ET  | Source: Booking Health Langenfeld, Germany, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Booking Health, a…

10 months ago

Del Bigtree and ICAN Announce Senate Hearing on Science and Corruption, Featuring Groundbreaking Study and Announce Documentary, “An Inconvenient Study”

WASHINGTON, DC, Sept. 09, 2025 (GLOBE NEWSWIRE) -- The Informed Consent Action Network (ICAN), led by Emmy Award-winning producer and…

10 months ago

IPSEN – Buy-back programme – Art 5 of MAR – Week 36 – 2025

Aggregated presentation by day and by marketStatement of transactions in own shares from 1st September to 5th September 2025       Name of…

10 months ago

Harrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030

September 08, 2025 17:57 ET  | Source: Harrow, Inc. NASHVILLE, Tenn., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider…

10 months ago

Onco360 Has Been Selected as a National Specialty Pharmacy Partner for Wayrilz (rilzabrutinib)

LOUISVILLE, Ky., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a…

10 months ago

NurExone Receives U.S. Patent Allowance for Exosome Manufacturing, Strengthening Supply Chain Readiness

TORONTO and HAIFA, Israel, Sept. 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone”…

10 months ago

InnoCare Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Marginal Zone Lymphoma in Singapore

BEIJING, Sept. 07, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer…

10 months ago

Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis

September 07, 2025 18:25 ET  | Source: Dianthus Therapeutics, Inc. NEW YORK and WALTHAM, Mass., Sept. 07, 2025 (GLOBE NEWSWIRE)…

10 months ago